← Back to medicines

Galvus 50 mg is a Product of the Generic Vildagliptin

Galvus 50 mg belongs to the generic category of Vildagliptin. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Galvus 50 mg. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Vildagliptin and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Medicine Image
Rx

Galvus 50 mg

Nevian Lifescience PLC · Tablet

Generic

Vildagliptin

Strength50 mg
Total Strip2
Strip Size14
Unit Price
32

/ Piece

Order Now

Description of Galvus 50 mg

Galvus 50 mg may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Galvus 50 mg is provided below to help users gain a clear understanding of this medicine.

What Is Galvus 50 mg Indications and Uses?

Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy and in dual combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin when diet, exercise and a single antidiabetic agent do not result in adequate glycemic control.


Pharmacology (Source, Chemical and Physical Composition) Of Galvus 50 mg

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, Vildagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.


Dosage And Administration of Galvus 50 mg

The recommended dose of Vildagliptin is-

50 mg or 100 mg daily for monotherapy.
50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione;
50 mg once daily in the morning when used in dual combination with a Sulphonylurea.

Vildagliptin may be taken with or without a meal. No dosage adjustment is required in the elderly, or in patients with mild renal impairment.Pediatric use: Vildagliptin is not recommended in patients 18 years of age.


Drug Interactions of Galvus 50 mg

In pharmacokinetic studies, no interactions were seen with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan or simvastatin. As with other oral antidiabetic medicinal products the glucose-lowering effect of Vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.


Side Effects of Galvus 50 mg

The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. A rare case of hepatic dysfunction is seen. Clinical trials of up to and more than 2 years duration did not show any additional safety signals or unforeseen risks when using this combination.


Use During Pregnancy and Lactation

Vildagliptin should not be used in pregnancy. Vildagliptin should not be used during lactation.


Precautions And Warnings for Galvus 50 mg

Caution should be exercised in patients aged 75 years and older due to limited clinical experience. It is recommended that LFTs are monitored prior to initiation of Vildagliptin, at three-monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality returns to normal. If AST or ALT persists at 3xULN, Vildagliptin treatment should be stopped. Patients who develop jaundice or other signs of liver dysfunction should discontinue Vildagliptin. Following the withdrawal of treatment with Vildagliptin and LFT normalization, treatment with Vildagliptin should not be reinitiated. Due to limited clinical experience, use with caution in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II, and do not use in patients with NYHA functional class III IV.


Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor


Storage Conditions of It

Store below 30°C temperature & keep away from light & moisture. Keep out of reach of children.

Data Source: Data source of Indications and Usages, Pharmacology, Dosage & Administration, Drug Interactions, Side Effects, Use during Pregnancy & Lactation, Precautions & Warnings, Use in Special Populations, Therapeutic Class, and Storage Conditions is the concerned medicine company or respective organization.

Alternative Medicines

⚠ Disclaimer

The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

allsomadhan logo

N:B-All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines"

Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved

DBID

Registration ID: 176322642

Trade License: TRAD/DNCC/040904/2023

Payment Methods
google play storeapple store
Chat with us